Hello Sir,
Hope you are doing well.
Recently, I was going through the con-call of Apex Frozen Foods which exports processed shrimps to US, EU, China and other markets.
The demand from US continues to be low. However, things might start turning favorable for the company and the sector with the imposition of Anti-Dumping (AD) and Countervailing Duties (CVD) on Ecuador and Indonesia.
To understand the company better, we have shared notes from the Q4 FY 24 con-call of the company. Before that:
1 New Portfolio Stock Recommendation – Released a new stock recommendation for Alpha and Alpha + Members
- Key beneficiary of strong growth in Real Estate segment
- 100% + increase in sales in last 3 years and management targeting 20-30% sales CAGR for the next few years
- Improvement in product mix resulting in higher margins and ticket size
- Improving balance sheet with reduction in net debt and working capital days
- Attractive valuations and value unlocking through demerger
You can get the detailed report on the above stock and other recommendations by signing up HERE
APEX Frozen – Notes from Q4 FY 24 con-call
– Sales
- Net revenue for Q4 FY 24 came in at Rs 162 crores lower than the revenue of Rs 212 crores in the Q4 FY 23, mainly due to the subdued demand from our key market which is USA and overall lowered global shrimp prices
- The total volumes sold by our company stood at 2,302 MT in Q4 FY 24 as against 2,851 MT in the Q4 FY 23. However, there is a recovery from the Q3 FY 24 where the volume stood at 2,117 MT
- The preliminary CVD imposed by the USA on Indian frozen shrimp at 4.36% also acted as an additional dampener
- On the positive side, however, our shrimp sales to the European Union continue to do well, sales to the EU posted a growth of 31% YOY in FY 24
- This growth is only from our Ready-to-Cook products as we still await regulatory approvals for our high value added Ready-to-Eat products in the EU market
– Capacity Utilization
- it is 33% currently, last year it was 45%, that is overall capacity utilization
- With regard to the RTE sale, it was 22% last year and this year it is 16%
– Growth Initiatives
- We have been taking steps with regard to setting up our wholly-owned subsidiary in the US, mainly for support with regard to logistics and also market development in the US and the rest of North America
- We are even looking at exploring the Scandinavian side of the European Union
- Going into FY’25, we are exploring newer markets there too, along with a few other markets in Asia
– Shrimps Supply
- At the global level, of course, Ecuador shrimp supply continues to add some pressure on the realizations
- There definitely has been some conservative approach with the farmers especially towards the end of FY 24 and the beginning of FY 25, there’s been some conservative approach
- If you see since 2013, these pretty much have been like the historically low numbers, so almost like a decade low farm gate prices were there in the year FY 24. So, that definitely had an effect a little bit on the overall farmers psychic with regard to how many of acres of farm he should be doing
– AD and CVD duties
- The CVD rate on Ecuador preliminarily is 2.89%
- Ecuador has also been levied an anti-dumping, this is preliminary, antidumping duty of 10.58%. Earlier, both the duties were zero
- Indonesia on a preliminary basis has been awarded an anti-dumping duty rate of 6.3%. With regard to Indonesia, they do not have any CVD, pretty much they are at 0%
- India has been levied a countervailing duty of 4.36%, again, which is also preliminary
- Regarding the anti-dumping duty rate, India, it’s 1.35% which has been the case for the past four years in the case of India
- Definitely, as the new duties come into play even to other countries like Ecuador and Indonesia, which did not have any type of duties until now, we are a bit positive that it is more of a level playing field for all supplying nations of shrimp into the US market
– Balance Sheet
- Gross debt was reduced by Rs 60 crores from Rs 167 crores as of 31st March 2022 to Rs 107 crores as of 31st March 2024
- We also have a significant amount of receivables pending through scripts and duty drawbacks with the Government of India, which we are likely to see those being received in Q1 FY’25, thereby which would also enable us to reduce our borrowing even further
(End)
Disclaimer: This is not a recommendation to buy/sell Apex Frozen Foods. The securities quoted are for illustration only and are not recommendatory.
Best Regards,
Ekansh Mittal
Research Analyst
Web: https://www.katalystwealth.
SEBI Research Analyst Registration No. INH100001690
Research Analyst Details
Name: Ekansh Mittal Email Id: [email protected] Ph: +91 727 5050062
Details of Associate: Not Applicable
Analyst Certification: The Analyst certify (ies) that the views expressed herein accurately reflect his (their) personal view(s) about the subject security (ies) and issuer(s) and that no part of his (their) compensation was, is or will be directly or indirectly related to the specific recommendation(s) or views contained in this research report.
Disclaimer: http://www.
Address – 7, Panch Ratan, 7/128, Swaroop Nagar, Kanpur – 208002, Contact No. – +91-7275050062
Compliance Officer – Mr. Ekansh Mittal, +91-9818866676, ekansh@
Grievance Redressal – Mittal Consulting, grievances@
“Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors”.
“Investment in securities market are subject to market risks. Read all the related documents carefully before investing.”
The views expressed are based solely on information available publicly and believed to be true. Investors are advised to independently evaluate the market conditions/risks involved before making any investment decision
This report is for the personal information of the authorized recipient and does not construe to be any investment, legal or taxation advice to you. Ekansh Mittal/Mittal Consulting/Katalyst Wealth is not soliciting any action based upon it. This report is not for public distribution and has been furnished to you solely for your information and should not be reproduced or redistributed to any other person in any form. This document is provided for assistance only and is not intended to be and must not alone be taken as the basis for an investment decision. Ekansh Mittal or any of its affiliates or employees shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. Neither Ekansh Mittal, nor its employees, agents nor representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. Ekansh Mittal/Mittal Consulting or any of its affiliates or employees do not provide, at any time, any express or implied warranty of any kind, regarding any matter pertaining to this report, including without limitation the implied warranties of merchantability, fitness for a particular purpose, and non-infringement.
The recipients of this report should rely on their own investigations. Ekansh Mittal/Mittal Consulting and/or its affiliates and/or employees may have interests/ positions, financial or otherwise in the securities mentioned in this report. Mittal Consulting has incorporated adequate disclosures in this document. This should, however, not be treated as endorsement of the views expressed in the report.
We submit that no material disciplinary action has been taken on Ekansh Mittal by any regulatory authority impacting Equity Research Analysis.
Disclaimer: You can access it here – LINK
Whether the research analyst or research entity or his associate or his relative has any financial interest in the subject company/companies and the nature of such financial interest – No
Whether the research analyst or research entity or his associates or his relatives have actual/beneficial ownership of 1% or more securities of the subject company (at the end of the month immediately preceding the date of publication of the research report or date of the public appearance) – No
Whether the research analyst or research entity or his associate or his relative has any other material conflict of interest at the time of publication of the research report or at the time of public appearance – No
Whether it or its associates have received any compensation from the subject company in the past twelve months – No
Whether it or its associates have managed or co-managed public offering of securities for the subject company in the past 12 months – No
Whether it or its associates have received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past 12 months – No
Whether it or its associates have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months – No
Whether the subject company is or was a client during twelve months preceding the date of distribution of the research report and the types of services provided – No
Whether the research analyst has served as an officer, director or employee of the subject company – No
Whether the research analyst or research entity has been engaged in market making activity for the subject company – No